Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)

Trial Profile

Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Rolapitant (Primary) ; Dexamethasone; Doxorubicin; Fosaprepitant; Ifosfamide; Mesna; Ondansetron; Vincristine
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Oct 2019.
    • 12 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 20 May 2016 The protocol has been amended to now include 2 parts. Patients in part 1 receive Rolapitant and patients in part 2 receive either Rolapitant or Fosaprepitant. Hence the patients no. has increased and the treatment table has been amended to include 3 arms instead of 2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top